Literature DB >> 14762986

Benefit-risk analysis: examples using quantitative methods.

William L Holden1, Juhaeri Juhaeri, Wanju Dai.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 14762986     DOI： 10.1002/pds.794

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  8 in total

1.  A model for decision support in signal triage.

Authors:  Bennett Levitan; Chuen L Yee; Leo Russo; Richard Bayney; Adrian P Thomas; Stephen L Klincewicz
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 2.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

Review 3.  A framework for organizing and selecting quantitative approaches for benefit-harm assessment.

Authors:  Milo A Puhan; Sonal Singh; Carlos O Weiss; Ravi Varadhan; Cynthia M Boyd
Journal:  BMC Med Res Methodol       Date:  2012-11-19       Impact factor: 4.615

Review 4.  Assessing the benefit: risk ratio of a drug--randomized and naturalistic evidence.

Authors:  François Curtin; Pierre Schulz
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

5.  Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis.

Authors:  Alejandro Lazo-Langner; Marc A Rodger; Nicholas J Barrowman; Tim Ramsay; Philip S Wells; Douglas A Coyle
Journal:  BMC Med Res Methodol       Date:  2012-01-10       Impact factor: 4.615

6.  Ranking adverse drug reactions with crowdsourcing.

Authors:  Assaf Gottlieb; Robert Hoehndorf; Michel Dumontier; Russ B Altman
Journal:  J Med Internet Res       Date:  2015-03-23       Impact factor: 5.428

Review 7.  Benefit-risk evaluation: the past, present and future.

Authors:  Juhaeri Juhaeri
Journal:  Ther Adv Drug Saf       Date:  2019-08-26

8.  Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.

Authors:  Miranda Davies; Vicki Osborne; Samantha Lane; Debabrata Roy; Sandeep Dhanda; Alison Evans; Saad Shakir
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.